CervoMed Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRVO Nasdaq 2834 www.cervomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CervoMed Inc.

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Aug 6th, 2026 3:20 pm
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates - Aug 5th, 2026 7:00 am
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Aug 5th, 2026 5:30 am
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - Aug 4th, 2026 3:15 am
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - Jul 14th, 2026 5:30 am
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia - Jul 9th, 2026 5:30 am
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 - Jul 6th, 2026 5:30 am
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Jun 22nd, 2026 2:05 pm
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Jun 18th, 2026 11:55 am
Top Midday Gainers - Jun 18th, 2026 11:32 am
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Jun 18th, 2026 10:35 am
CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO) - Jun 18th, 2026 8:08 am
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 - Jun 18th, 2026 5:00 am
CervoMed Insiders Lose Out As Stock Sinks To US$2.45 - Jun 14th, 2026 6:14 am
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - Jun 12th, 2026 5:30 am
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today? - Jun 10th, 2026 6:34 am
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies - Jun 10th, 2026 5:30 am
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates - May 18th, 2026 5:30 am
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 5:05 pm
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2026 5:10 am